Most of the multiple myeloma (MM) cell lines were also sensitive to the genetic depletion of MEN1, but none of them were sensitive to the inhibitor of MEN1–KMT2A interaction VTP50469 at therapeutically relevant doses. The gene discussed is MEN1; the disease is Miyoshi myopathy.